Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01204
|
|||||
| Drug Name |
Norfloxacin
|
|||||
| Synonyms |
1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; AM 0715; AM 715; AM-0715; AM-715; AM0715; Apo-Norflox (TN); Baccidal; Barazan; Chibroxin; Chibroxin (TN); Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; Fulgram; Insensye (TN); Lexinor; MK 0366; MK 366; MK-0366; MK-366; MK0366; MK366; Merck Brand of Norfloxacin; NFLX; Norflo; Norflohexal (TN); Norfloxacin (JP15/USP/INN); Norfloxacin Merck Brand; Norfloxacin [USAN:BAN:INN:JAN]; Norfloxacine; Norfloxacine [INN-French]; Norfloxacino; Norfloxacino [INN-Spanish]; Norfloxacinum; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin; Noroxin (TN); Nufloxib (TN); Roxin (TN); Sebercim; Utin (TN); Utinor (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Urinary tract infections [ICD11: GC08] | Approved | [1] | |||
| Gynecological infections [ICD11: GA6Z] | Approved | [1] | ||||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H18FN3O3
|
|||||
| Canonical SMILES |
CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
|
|||||
| InChI |
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
|
|||||
| InChIKey |
OGJPXUAPXNRGGI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 70458-96-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 319.33 | Topological Polar Surface Area | 72.9 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
-1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321598
, 11112831
, 11335259
, 11360498
, 11363911
, 11366473
, 11369035
, 11371707
, 11374005
, 11377197
, 11461470
, 11466249
, 11467369
, 11484909
, 11485918
, 11488833
, 11490340
, 11492268
, 11494831
, 12013332
, 14715876
, 14874649
, 26611845
, 26680206
, 26746929
, 26746930
, 29223630
, 3205552
, 46508634
, 4712110
, 47440088
, 47440089
, 47440090
, 47515159
, 47736303
, 47736304
, 47810598
, 47959570
, 47959571
, 48034947
, 49698389
, 50042536
, 50100528
, 597742
, 7847277
, 7980171
, 8149451
, 8152796
, 855614
, 8912
|
|||||
| ChEBI ID |
CHEBI:100246
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| References | ||||||
| 1 | Norfloxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5. | |||||
| 3 | Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94. | |||||
| 4 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.